Published in Business

CooperVision announces myopia management updates and plans

Alex Delaney-Gesing

This is editorially independent content
5 min read

CooperVision announced a series of ongoing investments in myopia management as the company continues to offer support in the global fight against the disease.

Where to start?

First up in the company’s announcements: The creation of a new myopia-targeted executive position.

Plus: CooperVision has also added managerial positions “specific to customer engagement and new product development,” with the intent for these roles to collectively "transform the myopia category for long-term success.”

Nice! What else?

Next up: New research and development projects.

What this includes: Clinical investigations into:

  • Novel optical designs (see here for related research)
  • Novel treatments
  • Foundational concepts relating to myopia’s onset and progression

Included among these investigations: A multi-site clinical study evaluating a next-generation soft contact lens CooperVision is developing for myopia control.

  • Notably: This is the first mention of such a lens by the company; however, CooperVision is currently not disclosing any additional information on the study (and yes, we asked).

Doesn’t the company already have a myopia-targeted contact lens?

Indeed it does: MiSight 1 day.

What it is: An FDA-approved (in 2019), single-use and disposable soft contact designed specifically for myopia control to slow myopia progression in pediatric patients aged 8-12 at treatment initiation.

  • See here for safety and fitting information

And what was notable about this lens?

When approved, MiSight became the first contact lens available on the U.S. market indicated to slow myopia progression in pediatric patients—and is still the only such lens.

The basis for that approval: Real-world data as well as positive findings from a 3-year, parallel group, randomized, controlled, double-masked clinical trial conducted at four clinical sites.

  • The findings: For the entire 3-year period, myopia progression among MiSight-wearing patients was less than those wearing conventional soft contact lenses—and axial length change of each eyeball for these patients was also less.
    • Plus: In 2021, the company released positive 7-year data from “the world’s longest continuous running soft contact lens trial for myopia control.”

Speaking of clinical research, anything on the horizon?

Yes! The company is collaborating with Manchester University’s School of Optometry and Centre for Health Economics on a United Kingdom-based program that will explore health economics issues around myopia and myopia control.

Funded by CooperVision, the 4-year program is expected to commence in April 2025 with three key objectives:

  • Complete a systematic review and evidence synthesis of literature on the cost-of-illness of myopia and key therapeutic interventions
  • Construct a cost of illness model to determine the economic burden of the major deleterious consequences of myopia (e.g., myopic maculopathy).
  • Determine the incremental cost-effectiveness of key therapeutic interventions to manage myopia compared with care as usual for children and young people.

Preliminary reporting is expected in 2026.

Sounds like a lot is in the works.

In the works and also ongoing.

The company is also a sponsor of global efforts from organizations like International Myopia Institute, the World Society of Paediatric Ophthalmology and Strabismus, and the International Agency for the Prevention of Blindness.

As a bonus: Check out some of our past coverage on CooperVision’s ongoing myopia-targeted initiatives:

How would you rate the quality of this content?

Share
Copy Link
Share
Copy Link
Search
Subscribe
Jobs
Events